search
Back to results

Dry Eye Disease in the Vitamin D and Omega-3 Trial (VITAL)

Primary Purpose

Dry Eye Disease

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Omega-3 fatty acids (fish oil)
Vitamin D3
Vitamin D3 placebo
Fish oil placebo
Sponsored by
Brigham and Women's Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Dry Eye Disease focused on measuring Dry eye disease, incidence, progression

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • All participants in VITAL (NCT 01169259) are eligible to participate in this ancillary study.

Exclusion Criteria:

  • None

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Active Comparator

    Active Comparator

    Placebo Comparator

    Active Comparator

    Arm Label

    Vitamin D + fish oil placebo

    Vitamin D placebo + fish oil

    Vitamin D placebo + fish oil placebo

    Vitamin D + fish oil

    Arm Description

    Vitamin D3 (cholecalciferol), 2000 IU per day Fish oil placebo

    Vitamin D placebo Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])

    Vitamin D placebo fish oil placebo

    Vitamin D (cholecalciferol), 2000 IU per day Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])

    Outcomes

    Primary Outcome Measures

    Dry Eye Disease
    Report of a diagnosis of dry eye disease confirmed by medical record review.

    Secondary Outcome Measures

    Full Information

    First Posted
    June 15, 2013
    Last Updated
    July 27, 2019
    Sponsor
    Brigham and Women's Hospital
    Collaborators
    National Eye Institute (NEI)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01880463
    Brief Title
    Dry Eye Disease in the Vitamin D and Omega-3 Trial (VITAL)
    Official Title
    Dry Eye Disease in the Vitamin D and Omega-3 Trial (VITAL)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2019
    Overall Recruitment Status
    Unknown status
    Study Start Date
    July 2010 (undefined)
    Primary Completion Date
    December 2020 (Anticipated)
    Study Completion Date
    December 2021 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Brigham and Women's Hospital
    Collaborators
    National Eye Institute (NEI)

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The VITamin D and OmegA-3 Trial (VITAL; NCT 01169259) is a randomized clinical trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among participants in VITAL and will examine whether omega-3 fatty acids or vitamin D3, compared to placebo, reduce the incidence and/or progression of dry eye disease.
    Detailed Description
    This ancillary study to VITAL will examine the efficacy of omega-3 fatty acids and vitamin D3 in prevention of dry eye disease. The primary aims are to test whether omega-3 fatty acid supplementation (1) reduces the incidence of dry eye disease, and (2) improves the natural history of dry eye disease by relieving symptoms and other impacts on quality of life. Secondary aims are to estimate the incidence of dry eye disease in the US, prospectively examine the natural history of dry disease, explore factors that could modify or influence the impact of omega-3 fatty acid supplementation, evaluate the interrelationship of dry eye disease and depression, and test for possible independent or joint effects of vitamin D3 supplementation in the incidence and natural history of dry eye disease.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Dry Eye Disease
    Keywords
    Dry eye disease, incidence, progression

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Factorial Assignment
    Masking
    ParticipantInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    25875 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Vitamin D + fish oil placebo
    Arm Type
    Active Comparator
    Arm Description
    Vitamin D3 (cholecalciferol), 2000 IU per day Fish oil placebo
    Arm Title
    Vitamin D placebo + fish oil
    Arm Type
    Active Comparator
    Arm Description
    Vitamin D placebo Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
    Arm Title
    Vitamin D placebo + fish oil placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Vitamin D placebo fish oil placebo
    Arm Title
    Vitamin D + fish oil
    Arm Type
    Active Comparator
    Arm Description
    Vitamin D (cholecalciferol), 2000 IU per day Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
    Intervention Type
    Drug
    Intervention Name(s)
    Omega-3 fatty acids (fish oil)
    Other Intervention Name(s)
    Omacor
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Vitamin D3
    Other Intervention Name(s)
    cholecalciferol
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Vitamin D3 placebo
    Intervention Type
    Drug
    Intervention Name(s)
    Fish oil placebo
    Primary Outcome Measure Information:
    Title
    Dry Eye Disease
    Description
    Report of a diagnosis of dry eye disease confirmed by medical record review.
    Time Frame
    5 years

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    50 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: All participants in VITAL (NCT 01169259) are eligible to participate in this ancillary study. Exclusion Criteria: None

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    35679030
    Citation
    Christen WG, Cook NR, Manson JE, Buring JE, Lee IM, Bubes V, Friedenberg G, Dushkes R, Smith D, Schaumberg DA; VITAL Research Group. Efficacy of Marine omega-3 Fatty Acid Supplementation vs Placebo in Reducing Incidence of Dry Eye Disease in Healthy US Adults: A Randomized Clinical Trial. JAMA Ophthalmol. 2022 Jul 1;140(7):707-714. doi: 10.1001/jamaophthalmol.2022.1818. Erratum In: JAMA Ophthalmol. 2022 Jul 21;:null.
    Results Reference
    derived
    Links:
    URL
    http://vitalstudy.org
    Description
    Welcome to the VITAL Study website

    Learn more about this trial

    Dry Eye Disease in the Vitamin D and Omega-3 Trial (VITAL)

    We'll reach out to this number within 24 hrs